Amrinone是一种双吡啶衍生物。体外实验显示能使心房和心室肌的收缩力增强而不增加右房率。狗的体内实验显示能增加心排出量和降低心室充盈压,动脉压和心率则无明显改变。即使口服和静脉注射大剂量,亦不引起心律失常。唯一的毒性是在极高剂量时,可引起舒张压的轻度降低。Amri-none的强心作用机理与强心糖甙或儿茶酚胺不同,它不抑制Na~+—K~+ATP酶,其活性不能被β-肾上腺能阻滞,也不因心肌内儿茶酚胺的丢失而减弱,同时亦不改变环磷腺苷浓度和磷酸二酯酶活性。由于Amrinone口服有效,实验显示毒性低,使之有可能作为临床上治疗心力衰竭的强心药物。本文系 Amrinone is a bipyridine derivative. In vitro experiments have shown that the atrial and ventricular muscle contractility can increase without increasing the right atrial rate. Dogs’ in vivo experiments showed increased cardiac output and reduced ventricular filling pressure with no significant changes in arterial pressure and heart rate. Even oral and intravenous injection of high doses, nor cause arrhythmia. The only toxicity at very high doses, can cause a slight decrease in diastolic blood pressure. Unlike cardiac glycosides or catecholamines, Amri-none does not inhibit Na ~ + -K ~ + ATPase, its activity can not be blocked by β-adrenergic, nor is it due to the loss of myocardial catecholamines Diminished, while not changing the concentration of cyclic adenosine monophosphate and phosphodiesterase activity. Because of the oral effectiveness of Amrinone, experiments have shown low toxicity, making it potentially as a cardiotonic drug for the clinical treatment of heart failure. Department of this article